Virtu Financial LLC Bio N Tech Se Transaction History

Virtu Financial LLC

  • $1.43 Billion
  • Q2 2024

A detailed history of Virtu Financial LLC transactions in Bio N Tech Se stock. As of the latest transaction made, Virtu Financial LLC holds 19,742 shares of BNTX stock, worth $1.97 Million. This represents 0.11% of its overall portfolio holdings.

Number of Shares
19,742
Holding current value
$1.97 Million
% of portfolio
0.11%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 09, 2024
BUY
$80.36 - $102.87 $1.59 Million - $2.03 Million
19,742 New
19,742 $1.59 Million
Q4 2023

Feb 26, 2024
BUY
$90.91 - $112.75 $236,366 - $293,150
2,600 New
2,600 $274,000
Q2 2023

Jul 27, 2023
BUY
$102.58 - $129.66 $127,199 - $160,778
1,240 Added 22.57%
6,734 $727,000
Q1 2023

May 01, 2023
SELL
$122.57 - $153.67 $3.01 Million - $3.78 Million
-24,591 Reduced 81.74%
5,494 $684,000
Q4 2022

Feb 15, 2023
BUY
$118.43 - $186.05 $2.98 Million - $4.67 Million
25,126 Added 506.67%
30,085 $4.52 Million
Q3 2022

Nov 07, 2022
BUY
$127.65 - $183.11 $633,016 - $908,042
4,959 New
4,959 $669,000
Q1 2022

May 17, 2022
SELL
$126.25 - $231.85 $869,105 - $1.6 Million
-6,884 Closed
0 $0
Q4 2021

Feb 17, 2022
BUY
$216.64 - $362.52 $1.49 Million - $2.5 Million
6,884 New
6,884 $1.78 Million
Q1 2021

May 19, 2021
SELL
$85.73 - $119.5 $5.18 Million - $7.23 Million
-60,461 Closed
0 $0
Q4 2020

Feb 24, 2021
BUY
$72.71 - $129.54 $4.4 Million - $7.83 Million
60,461 New
60,461 $4.93 Million
Q3 2020

Dec 11, 2020
SELL
$57.81 - $104.17 $391,836 - $706,064
-6,778 Closed
0 $0
Q2 2020

Aug 07, 2020
BUY
$38.58 - $66.74 $261,495 - $452,363
6,778 New
6,778 $452,000

Others Institutions Holding BNTX

# of Institutions
358
Shares Held
38.4M
Call Options Held
2.45M
Put Options Held
2.29M
View Full List

About BioNTech SE

BNTX Quotes by TradingView
  • Ticker BNTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 242,684,992
  • Market Cap $24.2B
  • Description
  • BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II...
More about BNTX
Track This Portfolio

Track Virtu Financial LLC Portfolio

Follow Virtu Financial LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Virtu Financial LLC, based on Form 13F filings with the SEC.

News

Stay updated on Virtu Financial LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email